Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antisoma Completes Patient Enrolment For Phase III NSCLC Trial
Antisoma has reported that the ATTRACT-1 phase III trial of ASA404 in non-small cell lung cancer (NSCLC) has reached its enrolment target of 1,200 patients. ASA404 is a
Antisoma has reported that the ATTRACT-1 phase III trial of ASA404 in non-small cell lung cancer (NSCLC) has reached its enrolment target of 1,200 patients. ASA404 is a
Tioga Pharmaceuticals (Tioga) and Ono Pharmaceutical (Ono) has entered into an exclusive license agreement under which Ono has licensed rights to develop and commercialise asimadoline in Japan, South
Shire has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease,
Cell Biosciences has launched a service program to provide phosphoprotein analysis of pre-clinical samples for pharmaceutical and biotechnology companies. Under the Cell Biosciences Focus Assay Service program, client
Santhera Pharmaceuticals has announced that Catena will be made available on a named patient basis in Europe. Santhera’s Named Patient Program (NPP) allows healthcare professionals to prescribe the
Cordis has announced that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery
Huntsman has signed a “stalking horse” asset and equity purchase agreement pursuant to which its wholly-owned subsidiary Huntsman Pigments has agreed to acquire the following assets of Tronox
Abbott has announced at the European Society of Cardiology Congress the availability of its XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Roche has announced that the FDA has approved Valcyte (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to
Roche and Lonza have announced that Genentech Singapore, a wholly-owned member of the Roche Group, elected to exercise an option to purchase from Lonza its cell culture biologic